MacroGenics: This Top-Rated Stock Soars Big, But I’m Not Buying (NASDAQ:MGNX)


Cancer Detection

wildpixel

The Company

MacroGenics, Inc. (NASDAQ:MGNX) is a $526-million market cap biopharmaceutical company based in Maryland that focuses on developing and selling antibody-based treatments for cancer. Their approved product, MARGENZA, is used with chemotherapy to treat metastatic HER2-positive



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *